Cencora, Inc. (NYSE:COR) Stock Position Raised by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Cencora, Inc. (NYSE:COR - Free Report) by 4.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 357,299 shares of the company's stock after buying an additional 14,050 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.18% of Cencora worth $80,421,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in COR. New Millennium Group LLC bought a new position in shares of Cencora during the 2nd quarter valued at $26,000. MFA Wealth Advisors LLC bought a new position in Cencora during the second quarter valued at about $30,000. Concord Wealth Partners bought a new position in Cencora during the third quarter valued at about $30,000. LRI Investments LLC acquired a new stake in shares of Cencora in the first quarter worth about $31,000. Finally, SYSTM Wealth Solutions LLC acquired a new position in shares of Cencora during the 2nd quarter valued at about $36,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Performance

COR opened at $243.20 on Thursday. The stock has a market cap of $47.92 billion, a PE ratio of 32.38, a P/E/G ratio of 1.60 and a beta of 0.44. Cencora, Inc. has a 1 year low of $195.83 and a 1 year high of $251.56. The stock's 50 day simple moving average is $232.82 and its 200-day simple moving average is $231.29. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. This is an increase from Cencora's previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. Cencora's dividend payout ratio (DPR) is presently 29.29%.

Insider Activity

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now directly owns 285,088 shares of the company's stock, valued at approximately $67,223,750.40. This represents a 7.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 15.80% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on COR shares. StockNews.com downgraded Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. JPMorgan Chase & Co. raised their target price on shares of Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a research note on Wednesday, August 21st. Robert W. Baird boosted their target price on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Wells Fargo & Company raised their price target on Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a research report on Thursday, August 1st. Finally, Bank of America restated a "neutral" rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Cencora presently has an average rating of "Moderate Buy" and a consensus price target of $271.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.